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 The progression of prostate cancer is strongly influenced by complex signaling 
pathways.  The insulin-like growth factor I receptor (IGF-IR) and 1 integrins promote 
various cellular events such as migration and proliferation that are important to cancer 
development.  Both in vitro and in vivo techniques were implemented to investigate 
whether or not 1 integrins are upstream regulators of IGF-IR expression and signaling.  
In vitro, downregulation of 1 with small interfering RNA oligonucleotides (siRNA) 
causes subsequent downregulation of IGF-IR in human prostate cancer LNCaP cells.  In 
vivo, using a mouse model for prostate cancer (TRAMP, transgenic prostate 
adenocarcinoma mice) generated by simian virus 40 large T antigen (SV40-Tag), 
expression of IGF-IR was found to be comparable in prostate sections from wild type and 
prostate specific 1 conditionally ablated (1
pc-/-
) TRAMP mice.  Furthermore, the 
signaling downstream of IGF-IR was analyzed in LNCaP cells upon downregulation of 
1.  Surprisingly, the levels of phosphorylated Akt, a kinase previously determined to be 
downstream of IGF-IR, were not affected by downregulation of 1 integrins and IGF-IR.  
This study gives further insight to the regulatory relationship between 1 integrins and 
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1.1 Prostate cancer 
 Prostate cancer is the most frequently diagnosed cancer in men of Western 
countries with incidence rates on the rise worldwide (Lane et al., 2007).  It is estimated, 
in 2008, that 186,320 American men will be diagnosed with prostate cancer, representing 
the majority of all male cancers.  Because of its high prevalence, most men over 50 years 
old are screened for prostate cancer annually which helps with early detection and 
diagnosis.  Even so, prostate cancer is still one of the most deadly types of cancer for men 
in various geographical locations.  Nearly 1 out of every 6 prostate cancer cases develops 
invasive metastatic lesions that severely decrease the probability for survival.  In fact, 
2008 prostate cancer deaths are predicted at 28,660, 10% of all cancer related deaths in 
men, only surpassed in lethality by lung cancer (Jamel et al., 2008).  Treatment options 
include chemotherapy, radiation, androgen deprivation therapy and surgery, yet none 
have proven significantly successful (Lane et al., 2007).  However, ongoing prostate 
cancer research continues to aid in the development of more specific and effective 
treatments and contributes to the understanding of the mechanisms through which 
prostate cancer develops.      
 
1.2 TRAMP mouse model  
 Before the mid-nineties, a reliable animal model for studying prostate cancer was 
not yet developed.  Various attempts that have been previously made focused on using a 
variety of chemical or hormonal carcinogens for prostate transformation, which were 
inconsistent and unpredictable.  Greenberg and colleagues generated transgenic mice that 
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accurately model the progression of malignant prostate disease, called TRAMP.  
Pathological states in TRAMP mice can range from prostate hyperplasia to invasive 
adenocarcinoma, closely similar to the progression of prostate cancer in human beings.  
The rat probasin promoter directs prostate-specific expression of the SV40-Tag that binds 
and inactivates tumor suppressors retinoblastoma (Rb) and p53.  For this reason, cancer is 
only found in the prostate, even as early as 10 weeks of age (Greenberg et al., 1995).  
Today, the TRAMP model is frequently implemented for in vivo prostate cancer studies, 
such as those performed here.   
                              
Figure 1.  The normal murine prostate.   
A. Intact mouse prostate, bladder, and seminal vesicles.  B. Diagram of murine 
genitourinary (GU) bloc, urethra (UR) and prostate lobes: ventral prostate (VP), lateral 
prostate (LP), dorsal prostate (DP) and anterior prostate (CG); seminal vesicles (SV), 
ductus deferens (DD) and urinary bladder (UB) also shown. C. Removed GU bloc from 
A.  D. Same GU block as in A and C, yet transversely cut through urethra and seminal 
vesicles.  E. Histological cross-section of murine GU block; 1. urethra, 2. ductus 
deferens, 3. ampullary glands, 4. ventral prostate, 5. lateral prostate, 6. dorsal prostate 
(Shappell et al., 2004).  
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1.3 Integrins and growth factor receptors  
 Integrins are heterodimeric, transmembrane cell surface receptors that bind 
extracellular matrix (ECM) proteins to influence a number of cellular functions such as 
migration, differentiation, proliferation and survival.  Combinations of 18 known α and 8 
known  subunits are expressed based on cell type (Slack-Davis and Parsons, 2004).  
Members and ligands of the integrin family are listed in Table 1.   






1 Laminin, collagen 
2 Laminin, collagen, thrombospondin, E-cadherin, tenascin 
3A, 3B Laminin, collagen, fibronectin, entactin, thrombospondin, uPAR 
4 
Fibronectin, VCAM-1, osteopontin, ADAM, ICAM, MAdCAM-1, 
thrombospondin, Lu/BCAM, CD14, JAM-2, uPAR 
5 Fibronectin, L1, osteopontin, fibrillin, thrombospondin, ADAM, NOV 
6A, 6B, 
6X1, 6X2 
Laminin, thrombospondin, Cyr61, ADAM, uPAR 
7A, 7B Laminin 
8 Fibronectin, tenascin, nephronectin, vitronectin, osteopontin, TGF -LAP 
9 
Tenascin, VCAM-1, osteopontin, uPAR, plasmin, angiostatin, ADAM, 
VEGF-C, VEGF-D 
10 Collagen, laminin 
11 Collagen 
V Fibronectin, osteopontin, TGF -LAP, L1 
2 L ICAM 
M iC3b, fibrinogen, factor X, ICAM, heparin 
X iC3b, fibrinogen, collagen, ICAM, heparin 




Fibrinogen, fibronectin, von Willebrand factor, vitronectin, 
thrombospondin, disintegrin, osteopontin, Cyr61, ICAM, L1 
V 
Vitronectin, fibrinogen, fibronectin, von Willebrand factor, 
thrombospondin, fibrillin, tenascin, PECAM-1, BSP, ADAM, ICAM, FGF-
2, uPA, angiostatin, TGF -LAP, Del-1, L1, MMP, osteopontin, 
cardiotoxin, uPAR, plasmin, Cyr61, tumstatin, NOV 
4A, 4B, 
4C, 4D 
6A, 6B Laminin 
5A, 5B V Vitronectin, osteopontin, fibronectin, TGF -LAP, NOV, BSP, MFG-E8 
6 V Fibronectin, tenascin, vitronectin, TGF -LAP, osteopontin, ADAM 
7 4, IEL Fibronectin, VCAM, MAdCAM-1, osteopontin 
E E-cadherin 
8 V Vitronectin, laminin, TGF -LAP 
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Integrins have been shown to associate with receptor tyrosine kinases (RTKs i.e., 
growth factor receptors) to induce downstream signaling by a variety of mechanisms (Lee 
and Juliano, 2004) (Fig. 2).  One such proposed mechanism states that the transmembrane 
domain of integrins can recruit specific adaptor molecules to the plasma membrane and 
concentrate them in the proximity of growth factor receptors (GFRs), which can 
influence their activity (Fig. 2).  A second mechanism is that integrins can alter GFR 
localization.  Subcellular focal contacts are concentrations of signaling kinases and 
cytoskeleton proteins, including paxillin, talin and vinculin.  GFR signaling is, in turn, 
manipulated by these focal contacts (Fig. 2).  In the third mechanism, integrins can alter 
the rate of internalization and degradation of GFRs via ubiquitination; a hypothesis that 
remains to be tested (Alam et al., 2007).   
Integrin and GFR cross-talk has been widely investigated.  One study has shown 
that insulin-like growth factor receptor substrate 1 (IRS-1) phosphorylation and signaling 
via the PI3-kinase (PI3K) pathway is correlated with increased cell adhesion and 
interaction of IRS-1 with 51 (Reiss et al., 2001).  Platelet-derived growth factor 
receptor (PDGFR) activation increases vitronectin-associated vascular endothelium 
migration (Woodard et al., 1998).  PDGFR phosphorylation and protein levels decrease 
in response to cell detachment from the ECM (Baron and Schwartz, 2000).  c-Met 
activation can be inhibited by blocking activity of an integrin-associated protein, 
KAI1/CD82 (Sridhar and Miranti, 2006).  64 associates with c-Met receptor and 
assists in invasion (Trusolino et al., 2001).  11 down-regulation has shown to increase 
epithelial growth factor receptor (EGFR) and downstream Rac activation (Chen et al., 
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2007).  Levels of activated EGFR are also influenced by cell attachment to the ECM 
(Reginato et al., 2003). 
Modifications of integrin expression majorly contribute to tumor invasion and 
metastasis through altered affinity to ECM proteins, cytoskeleton stability changes and 
recruitment of proteolytic activity for basement membrane degradation.  In many 
different cancers, the integrin profile is modified due to selective pressure changes:  
alterations in ECM secretions and oncogene or tumor suppressor activity.  Integrin and 
RTK signaling can also disrupt cell-cell adhesion, largely contributing to tumor invasion 
and metastasis.  Integrins and RTKs are thought to regulate the internalization and 
transcription of E-cadherin, a molecule important in cell adhesion (Guo and Giancotti, 
2004).   
The polymerization of actin cytoskeleton molecules influences the mobility of 
cells.  Additionally, this is affected by integrin and RTK signaling to focal adhesion 
kinase (FAK) and Shc.  Signaling to Ras and subsequently ERK/MAPK cooperates with 
signaling from transforming growth factor  receptor to induce the transitional movement 
of malignant cells from epithelium to mesenchyme.  Some integrins, including v3, 
have been shown to recruit degradative enzymes such as matrix-metalloproteinase-2 
(MMP2) and its activator urokinase plasminogen activator (uPA) to the cell surface, 
destroying the basement membrane as the tumor progresses (Guo and Giancotti, 2004).  
Similarly in prostate carcinoma, the normal basal cell layer diminishes until the tumor 
cells contact the substratum.  Integrins interact with the substratum layer, potentiating 
tumor cell survival.  Tumor substratum is marked by the loss of laminin 5 and collagen 
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VII, playing a part in the modification of integrin profile in malignant prostate epithelium 
(Knudsen and Miranti, 2006).  
 
 
Figure 2.  Regulation of growth factor receptor signaling by integrins. 
The interaction of v1 with the ECM and PDGFR, IGF-IR or VEGFR results in FAK 
stimulation and cytoskeleton rearrangement, inducing collaborative downstream 
signaling to the MAPK pathway.  Recruitment  of Shc to PDGFR or EGFR causes 
additional recruitment of Grb2/Sos complex (left).  Association of 1 integrin and adaptor 
molecules and activation of FAK leads to downstream signaling to the MAPK pathway 
(middle).  Adhesion of v3 and 1 integrins to the ECM phosphorylates c-Src and 
recruits other adaptor molecules like Cas and Crk.  This complex of v3 and 1 
integrins, EGFR and adaptor molecules allows for activation of the MAPK pathway 
(right). 
 
Through various signaling mechanisms, GFRs and integrins can activate 
ERK/MAPK, contributing to cell proliferation (Fig. 2).  GFR mutation or overexpression 
can result in phosphorylation of integrin cytoplasmic domain, creating adaptor protein 
docking sites and thereby amplifying and activating ERK/MAPK (Fig. 2, middle).  
Integrins also have the ability to enhance GFR signaling through signaling intermediates 
such as p130Cas (Fig. 2, right).  It has been demonstrated, in vitro, that GFR activation of 
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Raf or MEK can be prevented by inhibition of integrin binding to ECM (Hood and 
Cheresh, 2002).  
 
1.4 1 integrins, IGF-IR and prostate cancer 
 The 1 integrin subunit exists as several cytoplasmic domain splice isoforms that 
directly affect integrin-mediated cell processes and signaling (Fornaro and Languino, 
1997).  Previous research has demonstrated that the commonly expressed and highly 
conserved 1A splice variant promotes and enhances cell proliferation and migration 
(Marcantonio and Hynes, 1988; Fornaro and Languino, 1997).  Antagonistically, the 1C 
splice variant, which contains an exclusive 48 amino acid sequence in its carboxy 
terminus, inhibits cell proliferation and is frequently upregulated in differentiated 
epithelium (Fornaro et al., 1995, 1998).  1C was found to be selectively downregulated 
in prostate adenocarcinoma, a consequence of transcriptional as well as pre- and post-
translational regulation (Fornaro et al., 1996; Moro et al., 2004).   
 The IGFs are known to be important to cellular growth and differentiation.  
Variations in this signaling axis are thought to be involved in malignant transition and are 
relevant to cancer grade and prognosis (Cardillo et al., 1996; Baserga, 2000).  Elevated 
serum levels of IGF-I have been proposed to be a risk factor in the development of 
malignant prostate disease (Chan et al., 1998).  Previous reports introduce contradictory 
evidence of IGF axis expression in prostate cancer, some pointing towards its 
downregulation (Tennant et al., 1996; Chott et al., 1999).  Other more recent studies have 
shown that IGF-IR protein and mRNA levels are increased in prostate cancer compared 
to benign prostate (Nickerson et al., 2001; Hellawell et al., 2002).   
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 The synergistic relationship between GFRs and integrins applies also to IGF-IR 
and 1 in prostate carcinoma.  1A integrins can influence basement membrane adhesion 
via IGF signaling, indicating that these molecules are involved in tumor migration.  1A 
was shown to promote IGF-IR phosphorylation and recruitment of IRS-1 for the 
activation of IGF downstream signaling.  On the other hand, 1C does not associate with 
IGF-IR or promote its phosphorylation.  1C inhibits cell growth by enhancing adaptor 
protein Gab1/Shp2 recruitment to the plasma membrane.  This research has shown that 
cytoplasmic variation in 1 integrins can modulate IGF-IR activities (Goel et al., 2004).  
The 1A integrin splice variant was demonstrated as necessary to prostate cancer cell 
proliferation and anchorage-independent growth through IGF-I signaling.  In early 
prostate transformation in TRAMP mice, both 1A and IGF-IR are upregulated, 
suggesting essential roles in tumor initiation.  1A integrins have the ability to direct 
IGF-IR to focal contacts and support downstream IGF signaling, whereas 1C integrins 
do not have this effect, potentiating IGF-IR inactivation in normal prostate (Goel et al., 
2005).  1 integrins have been demonstrated as important effectors in IGF-IR localization 
and signaling that fundamentally contribute to prostate cancer growth and migration.  
Despite these current findings, little is still known about the influence of 1 on IGF-IR 
expression in prostate cancer.   
 
1.5 Akt and prostate cancer 
 In addition to downstream mitogenic signaling via the Ras-MAPK/ERK pathway, 
IGF-IR also activates Akt (Pollack et al., 2004).  Akt is a serine/threonine kinase that is 
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most widely accepted as a cell survival mediator, but also functions in cell proliferation 
and growth.  For optimal activation of Akt, phosphorylation on both Thr308 and Ser473 
is required.  After activation, Akt signals to multiple components of the cell-death cycle, 
including BAD.  By phosphorylating BAD, Akt prevents BAD interaction with BCL-X, 
contributing to cell survival.  Akt phosphorylation of caspase-9 inhibits its proteolytic 
activity in apoptosis.  Through Akt signaling, both NF-B transcription and p53 
degradation are indirectly promoted; further augmenting Akt impact on cell survival.  Akt 
also affects G1/S transition by preventing the degradation of cyclin D1.  Expression of 
cell cycle inhibitors, p27 and p21 are inhibited by Akt signaling.  It is mainly the 
inactivation of the tumor suppressor PTEN in prostate cancer that causes the deregulation 
of Akt signaling, ultimately resulting in reduced cell apoptosis and prolonged cell 
survival (Vivanco and Sawyers, 2002).  Deregulation of Akt through IGF-IR expression 
may contribute to cell survival in prostate cancer. 
 
1.6 Project purpose 
 The purpose of this project was to evaluate the cross-talk between 1 integrins 
and IGF-IR in prostate cancer.  Since both 1 and IGF-IR are upregulated in prostate 
cancer and form a complex, further investigation into the interaction of these molecules 
may reveal more information about the initiation and progression of prostate cancer.  
However, not much is known regarding the mechanism that controls the expression of 
these molecules.  Specifically, 1 integrins were analyzed in vitro and in vivo as potential 
upstream regulators of IGF-IR expression and signaling.  Although constitutive Akt 
activation often occurs in prostate cancer due to disabling of PTEN, it is not known 
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whether or not 1 or IGF-IR control Akt activation.  Therefore, the activation of Akt was 






















2.  METHODS 
2.1 Cells and culture conditions 
 Human lymph node prostate cancer metastasis derived LNCaP cells (ATCC) were 
cultured in RPMI 1640 supplemented with 10% fetal bovine serum (FBS, Gemini 
Bioproduct), 100 units/mL penicillin, 100 g/mL streptomycin, sodium pyruvate and 
non-essential amino acids (all from Invitrogen).  The cells were stimulated with non-
metabolizable synthetic androgen analogue, R1881, and then transfected with siRNA 
(100 nM) using oligofectamine (Invitrogen) in serum-free media.  Following 4 hours of 
incubation, cells were fed complete medium with serum and incubated an additional 48 
hours.  The sequence of 1A siRNA was: sense strand 5’—
AUGGGACACGGGUGAAAAUTT—3’ and antisense strand 5’—
AUUUUCACCCGUGUCCCAUTT—3’.  The sequence of 1C siRNA was: sense strand 
5’—CCUCUGACUUCCAGAUUCCTT—3’ and antisense strand                                           
5’—GGAAUCUGGAAGUCAGAGGTT—3’.  The sequences were submitted to BLAST 
search to ensure that only 1A integrin was targeted by the siRNA and that the control 
sequences were not homologous to any known genes.  The siRNA specific to 1A and 
1C integrin were both synthesized by Dharmacon. 
 
2.2 Mice  
 TRAMP (B6), 1
loxP/loxP
 (B6;129) and PB-Cre4 (B6.D2) mice were generated and 
characterized by Dr. Goel in Dr. Languino’s lab.  1
loxP/loxP
 / TRAMP / PB-Cre4 
(TRAMP mice with conditional ablation of 1) and 1
loxP/loxP
 / TRAMP (TRAMP mice 
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with wt 1) were generated as described below.  The male PB-Cre4 and female 1
loxP/loxP
 
mice were mated and male offsprings expressing PB-Cre4 were backcrossed with female 
1
loxP/loxP
 to generate male 1
loxP/loxP
 / PB-Cre4 mice designated as 1
pc-/-
.  Similarly, 
female TRAMP and male 1
loxP/loxP
 were bred, resulting in the female offsprings which 
express TRAMP; these female mice were backcrossed with male 1
loxP/loxP
 to generate 
female 1
loxP/loxP
 / TRAMP.  Male 1
pc-/- 
mice were crossed with female 1
loxP/loxP
 / 
TRAMP to generate male 1
loxP/loxP
 / TRAMP designated as 1
wt
 / TRAMP and male 
1
pc-/-
 / TRAMP.  Only male 1
wt 
/ TRAMP and male 1
pc-/- 
/ TRAMP littermates were 
used in this project.   
 
2.3 Immunohistochemistry (IHC) 
 Prostate lobes from 1
wt 
/ TRAMP and 1
pc-/-
 / TRAMP micewere isolated, fixed 
in buffer-neutral formalin and embedded in paraffin.  Sections were stained with 
hematoxylin and eosin for histological analysis.  The mouse tissue sections prepared for 
IHC were placed on charged glass slides from paraffin-embedded blocks.  After baking in 
a 60°C oven for 2 hours, the slides were deparaffinized in three xylene washes and 
rehydrated in ascending concentrations of ethanol.  Antigen retrieval was achieved by 
boiling the slides in 10 mM sodium citrate, pH 6.0, for 23 minutes.  The slides were 
washed in 3% hydrogen peroxide to remove endogenous peroxidase activity.  Sections 
were blocked in 50% goat serum in TBS for 1 hour.  Primary antibody to IGF-IR 
subunit (2 g/mL, Santa Cruz), and negative control, rabbit IgG, were added to the 
sections for overnight incubation at 4°C.  Following several TBS washes, biotinylated 
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anti-rabbit IgG (Vector) was applied to the sections for 30 minutes at room temperature.  
Immunoperoxidase staining was carried out with diaminobenzidene solution (2.5 mg 
DAB powder in 5 mL H2O, plus 100 L 3% H2O2).  The slides were counterstained with 
Mayer’s hematoxylin and then dehydrated in decreasing ethanol concentrations.  The 
sections were fixed with a solution of 55% toluene and 45% dissolved polymers under a 
glass coverslip.  All the slides were examined and photographed by an Olympus BX41TF 
optical microscope equipped with an Evolutions MP 5.0 RTV digital camera.  The 
stained slides were reviewed by Dr. Garlick, a veterinary pathologist from Charles River 
Laboratories, for intensity of the staining dependent on lobe (anterior, dorsal, lateral and 
ventral) or by pathological state (prostatic intraepithelial neoplasia or PIN and invasive 
adenocarcinoma).  Staining intensity was given a rating on a scale of +1 (weak staining), 
+2 (moderate staining) or +3 (strong staining) (Armes et al., 1999). 
 
2.4 Immunoblotting 
 LNCaP cells, 48 hours after siRNA transfection, were lysed in 20 mM Tris pH 
7.5, 150 mM NaCl, 10% glycerol, 1% NP-40, 10 mM NaF, 1 mM NaVO4, 1 mM 
Na4O7P2, 2 M leupeptin, 2 M aprotinin, 1 mM phenylmethylsulfonyl fluoride (PMSF).  
Protein concentration was quantified using the BCA protein assay (Pierce 
Biotechnology).  Total cell lysate was resolved by 10% SDS-PAGE under reducing 
conditions and transferred onto a PVDF membrane.  The membrane was blocked with 
5% non-fat dry milk in TBS-T for 1 hour at room temperature.  The membrane was 
immunoblotted with monoclonal antibody to 1 integrin (BD Transfection Laboratories), 
and polyclonal antibodies to IGF-IR subunit, phosphorylated Akt and total Akt (all 
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from Santa Cruz).  Proteins were visualized with ECL reagent (Boston Bioproducts) and 





















3.1 1 integrins modulate IGF-IR expression     
 Cell lysates from human prostate cancer LNCaP cells were analyzed for protein 
expression of the IGF-IR.  Immunoblotting was performed on three sets of LNCaP lysate:  
cells treated with non-metabolizable, synthetic androgen analogue, R1881, cells treated 
with R1881 and transfected with siRNA to 1C and cells treated with R1881 and 
transfected with siRNA to 1A.  LNCaP cells do not express the 1C integrin splice 
variant, so 1C siRNA does not interfere with 1 integrin expression.  For this reason, 
1C siRNA was used as a siRNA negative control.  However, the cells do express the 
1A variant, the expression of which is susceptible to downregulation by siRNA 
specifically targeting the 1A sequence.   
 Detection of 1 integrins with a monoclonal antibody revealed a 130-140 KDa 
protein expressed in cells only supplemented with R1881 as well as cells that were 
transfected with the control siRNA.  In cells with siRNA to 1A, the level of 1 was 
significantly decreased (Fig. 3).  When the membrane was probed with a polyclonal 
antibody to IGF-IR, the results show that IGF-IR expression was markedly reduced in 
cells transfected with siRNA to 1A (Fig. 3).  Comparing the band intensities with that of 
the Akt loading control, both 1 and IGF-IR were both significantly downregulated (Fig. 
3).  The results suggest that IGF-IR and 1 integrins are closely associated and more 
specifically that 1 integrins may play a key role in regulating the expression of IGF-IR.   
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Figure 3. Decrease of 1 expression by siRNA in LNCaP cells subsequently 
downregulate expression of IGF-IR.  LNCaP cells transfected with siRNA to 1C or 
1A were stimulated with R1881 (synthetic androgen) and cell lysate was  
immunoblotted using an antibody to 1 integrin, IGF-IR or Akt.   1C siRNA was used as 
a negative control.  The results of this experiment were reproduced several times.   
 
 
3.2 IGF-IR expression in 1
pc-/-
/TRAMP mice  
 After determining that IGF-IR expression decreases as a result of 1 
downregulation in vitro, the focus was shifted to an in vivo approach.  Tissue sections 
from the murine prostate cancer model, TRAMP, were stained with an antibody specific 
for IGF-IR.  IGF-IR expression was compared in 1
wt
 / TRAMP and 1
pc-/-
 / TRAMP 
mice to determine the influence of 1 on IGF-IR in vivo.  Semi-quantitative 
immunohistochemical analysis of prostate tissue from these mice indicates that IGF-IR 
expression is localized in the prostate epithelium cytoplasm and, in some cases, nucleus 
(Fig. 4A-H).   
 Histological examination of the immunostained slides was performed by a 
veterinary pathologist who compared overall staining intensity between the four major 
lobes as well as the intensity of non-invasive prostate intraepithelial neoplasia (PIN) and 
invasive adenocarcinoma lesions to baseline staining in normal glands (Fig. 4I and J).  
For the majority of mouse cases (19 total), staining was light and minimal, a rating of +1 
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(Fig. 4I and J).  Only a few cases actually displayed some higher, moderate intensity of 
staining, a rating of +2 (Fig. 4I and J).  Since only a few cases, independent of 1 
expression by lobe or lesion type, attained a higher staining intensity of IGF-IR, it was 
concluded that there was no significant correlation in these results.   
 
 
Figure 4. In vivo IGF-IR expression is unaffected in 1
pc-/- 
TRAMP mice.   
A-H. Representative images of TRAMP mouse prostate sections stained using an 
antibody to IGF-IR, wild type (A-D) and 1
pc-/- 
TRAMP mice (E-H).  Panels A, C, E 
and G show negative control staining with Rabbit IgG (RbIgG). I. Rating of overall 
IGF-IR staining intensity in prostate lobes (anterior, lateral, dorsal or ventral).  J. 
Rating of IGF-IR staining intensity in PIN or adenocarcinoma lesions compared to 




3.3 Downregulation of 1 and IGF-IR does not affect activated Akt levels   
 Additionally, the downstream signaling pathways of IGF-IR were examined.  
LNCaP cell lysates were analyzed for phosphorylated Akt (p-Akt) using the same 
conditions in which 1 and IGF-IR were proven to be downregulated.  Downstream of 
insulin and IGF pathways, Akt is phosphorylated on serine residue 473.  A polyclonal 
antibody that detects this phosphorylation event, and therefore, Akt activation as a 
consequence of IGF-IR signaling, was used.  A 60 KDa protein band was revealed after 
probing for p-Akt (Fig. 5).  The results show that p-Akt levels were unmodified when 
comparing band intensities with the total Akt loading control even under 1 and IGF-IR 




Figure 5. Phosphorylated levels of Akt (p-Akt) are not altered when 1 and IGF-IR 
expression is downregulated by siRNA to 1 in LNCaP cells.  LNCaP cells transfected 
with siRNA to 1C or 1A were stimulated with R1881 and the cell lysate was  
immunoblotted using an antibody to p-Akt or Akt.  These results are representative of 










 In this study, it was found that the 1A integrins were essential in the regulation 
of IGF-IR expression in prostate cancer LNCaP cells (Fig. 6).  Downregulation of 1A by 
siRNA caused reduced expression of IGF-IR as well as 1A.  Similar results were 
obtained using siRNA to all 1 integrins (data not shown).  Past reports indicate the 
importance of 1A for IGF-IR mitogenic and tumorigenic activities in prostate cancer.  It 
was also shown that 1A and IGF-IR are both upregulated in TRAMP mice during the 
initial stages of the disease:  PIN and well differentiated (WD) tumors, suggesting 1A 
and IGF-IR are involved in the uncontrolled cell division at the start of cancer 
transformation (Goel et al., 2005).  By discovering the mechanism behind prostate cancer 
progression, possible therapeutic targets may be identified for treatment or prevention of 
the disease.  The full potential of RNA interference (RNAi) in treating human diseases is 
just beginning to be unraveled.  By directing RNAi towards the downregulation of 1A 
integrin expression during the pre-cancer or early cancer stages in the prostate, tumor 
progression may be inhibited before a more aggressive form develops and the likelihood 
of survival diminishes.   
 This study showed that in the TRAMP mouse model, IGF-IR expression was 
unaffected by loss of 1 in the prostate of these mice.  TRAMP mice were generated by 
expression of the SV40-Tag driven by a prostate specific rat probasin promoter.  The 
SV40-Tag interacts with tumor suppressor genes Rb and p53, causing their inactivation.  
This results in the development of adenocarcinoma in the prostate of these mice between 
10 and 20 weeks of age (Greenberg et al., 1995).  Kaplan et al. have previously analyzed 
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IGF expression in TRAMP mice, observing an increase in prostatic IGF-I mRNA levels 
in early PIN or WD carcinoma formation.  However, IGF-IR levels were found to be 
significantly decreased in metastatic and androgen-independent prostate cancer in 
TRAMP mice (Kaplan et al., 1999).  SV40-Tag has been shown to inhibit the binding of 
E2F complex to the IGF-I promoter, leading to an increase in IGF-I transcription (Porcu 
et al., 1994).  IGF-IR expression in SV40-Tag transformed cells has been proposed to be 
involved in maintaining proliferative, differentiated cells (Plymate et al., 1997).  A recent 
study by Bocchetta and colleagues revealed that Tag and p53 complex binds the IGF-I 
promoter, along with several other molecules including pRb.  It was noted that when p53 
was absent from SV40-Tag transformed cells, IGF-IR expression was decreased even 
though no association was found between Tag-p53 and IGF-IR promoter (Bocchetta et 
al., 2008).  Although IGF-IR may not be directly influenced by SV40-Tag expression in 
TRAMP mice, it may be the increase in IGF-I expression that is directing an autocrine 





mice.  Further experimentation is necessary to uncover the mechanism behind the indirect 
effects of SV40-Tag complexes on IGF axis expression.   
 Finally, this study found that when 1A integrins and IGF-IR are downregulated 
by siRNA, the levels of phosphorylated Akt remain unaltered in LNCaP cells (Fig. 6).  In 
many cases, constitutive Akt activation in prostate cancer is a result of PTEN tumor 
suppressor inactivation or growth factor stimulation (i.e., IGF-I) (Mujamder and Sellers, 
2004).  Akt activation in prostate cancer has been positively correlated with an increase 
in tumor grade (Kreisberg et al., 2004).  Androgen has been shown to activate Akt 
through the PI3K signaling pathway.  Androgen receptor (AR) interaction with the p85 
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regulatory subunit of PI3K as well as Src contributes to Akt activation (Sun et al., 2003).  
Through tyrosine kinase and small GTPase interaction with p85, PI3K activation can 
occur.  Src phosphorylation of p85 inactivates an inhibitory region on p85, allowing 
for activation of PI3K by small GTPases (Chan et al., 2002).  Androgen stimulation 
enhances the association between AR and p85 and activates Src kinase activity (Sun et 
al., 2003).  The non-metabolizable synthetic androgen analogue, R1881, used to stimulate 
the androgen-sensitive LNCaP cells may be activating Akt through a 1- or IGF receptor- 
independent pathway, which may include signaling pathways acted upon by other 
integrins.  Various reports in the literature demonstrate how androgen can activate the 
Akt survival pathway, yet the role of R1881 stimulation in prostate cancer LNCaP cells is 
not fully understood and still needs to be investigated.   
 In conclusion, the results of this project show that 1 integrins directly modulate 
IGF-IR expression and that Akt activation does not require 1 and IGF-IR in prostate 
cancer cells.   
  
 
Figure 6.  1 integrins are essential to IGF-IR expression and are not required for 
Akt activation.  Upon downregulation of 1 by siRNA, IGF-IR is not expressed in 
prostate cancer cells.  Phosphorylation of Akt occurs both dependently and independently 
of 1 and IGF-IR in prostate cancer cells 
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